Table 1.

Clinicopathologic features of the training set samples (17 cases)

Sample NoAgeGenderSiteHistologic typesSize (cm)Risk classification*Type of KIT mutationMetastatic site (first development)Metastasis time after diagnosis (mo)Follow-up time after diagnosis (mo)Follow-up status
168MStomachSpindle19HighWild-typePeritoneal metastasis816DOD
256MStomachSpindle38HighEX11 deletionPeritoneal metastasis79DOD
358MStomachSpindle13HighEX11 deletionPeritoneal metastasis611DOD
450FRectumSpindle4HighEX11 deletionPeritoneal metastasis1160AWD
551MStomachMixed (spindle main)12HighEX11 deletionPeritoneal metastasis569AWD
634MSmall intestineSpindle18HighEX11 deletionLiver metastasisAt diagnosis31AWD
768MSmall intestineMixed (spindle main)7HighEX9 insertionPeritoneal metastasisAt diagnosis9AWD
872FStomachSpindle25HighEX11 559 V-DPeritoneal metastasis58AWD
964FStomachSpindle3.5LowWild-type68NED
1064FStomachSpindle4LowWild-type81NED
1154MStomachSpindle10IntermediateEX11 560 V-G77NED
1268MSmall intestineSpindle3.7LowEX9 insertion50NED
1377MSmall intestineSpindle4LowWild-type69NED
1440FStomachSpindle10IntermediateEX11 559 V-D88NED
1552MStomachSpindle7IntermediateEX11 576 L-P62NED
1676MSmall intestineSpindle7IntermediateEX11 deletion48NED
1781MStomachSpindle5.5IntermediateEX11 559 V-D43NED
  • NOTE.PDGFR mutations: All samples lacked of PDGFR mutations. Detail data: Supplementary Table S1.

    Abbreviations: NED, no evidence of disease; AWD: alive with disease; DOD, dead of disease.

  • * Prognostic classification based on tumor size and MIB-1 grade (Hasegawa, T. et al. Hum Pathol. 2002, 33:669-676).